EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Reply to: Comments on “Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis”

Tianqi Gu, Anqi Lin, Haitao Wang, Jian Zhang, Peng Luo iD

International Journal of Cancer · 2023

DOI: 10.1002/ijc.34497 ↗

Kurz gefasst

Leserbrief in der Zeitschrift International Journal of Cancer, 2023. Verfasst von Tianqi Gu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Immunological, Drug-Related Side Effects and Adverse Reactions. Die Arbeit nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The data that support the findings of our study are available from the corresponding author upon reasonable request.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antineoplastic Agents, ImmunologicalDrug-Related Side Effects and Adverse ReactionsHumansBevacizumabImmune Checkpoint InhibitorsPharmacovigilanceAntibodies, Monoclonal, HumanizedRetrospective Studies

Substanzen

BevacizumabImmune Checkpoint InhibitorsAntineoplastic Agents, ImmunologicalAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
  • Thoracic Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

ORCID-Profile: Peng Luo

Zitieren

APA

Gu, T., Lin, A., Wang, H., Zhang, J., & Luo, P. (2023). Reply to: Comments on “Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis”. International Journal of Cancer. https://doi.org/10.1002/ijc.34497

Vancouver

Gu T, Lin A, Wang H, Zhang J, Luo P. Reply to: Comments on “Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis”. International Journal of Cancer. 2023. doi:10.1002/ijc.34497

BibTeX
@article{Gu2023,
  author = {Gu, Tianqi and Lin, Anqi and Wang, Haitao and Zhang, Jian and Luo, Peng},
  title = {Reply to: Comments on “Adverse reactions associated with immune checkpoint inhibitors and bevacizumab: A pharmacovigilance analysis”},
  journal = {International Journal of Cancer},
  year = {2023},
  doi = {10.1002/ijc.34497}
}
Kostenlos starten →